Published in Orphanet J Rare Dis on December 20, 2013
Hyper-IgD syndrome/mevalonate kinase deficiency: what is new? Semin Immunopathol (2015) 1.01
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clin Rheumatol (2014) 0.93
Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease. J Clin Invest (2015) 0.91
Key facts and hot spots on tumor necrosis factor receptor-associated periodic syndrome. Clin Rheumatol (2014) 0.91
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm (2015) 0.89
Treatment of hyperimmunoglobulinemia D syndrome with biologics in children: review of the literature and Finnish experience. Eur J Pediatr (2015) 0.88
Untangling the web of systemic autoinflammatory diseases. Mediators Inflamm (2014) 0.85
Mevalonate kinase deficiency: current perspectives. Appl Clin Genet (2016) 0.80
Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol (2014) 0.79
Alendronate, a double-edged sword acting in the mevalonate pathway. Mol Med Rep (2015) 0.79
The protean ocular involvement in monogenic autoinflammatory diseases: state of the art. Clin Rheumatol (2015) 0.75
Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J (2003) 1.90
Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet (1984) 1.79
Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) (2008) 1.74
The infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat (2008) 1.65
A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum (2006) 1.62
Enzymes of the mevalonate pathway of isoprenoid biosynthesis. Arch Biochem Biophys (2010) 1.60
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis (2012) 1.59
Synovial macrophage depletion with clodronate-containing liposomes in rheumatoid arthritis. Arthritis Rheum (2000) 1.32
Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1. Mol Immunol (2008) 1.22
Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. Pediatr Res (2008) 1.14
Mevalonate kinase deficiency: Evidence for a phenotypic continuum. Neurology (2004) 1.08
Defect in mevalonate pathway induces pyroptosis in Raw 264.7 murine monocytes. Apoptosis (2011) 1.07
Defective apoptosis of peripheral-blood lymphocytes in hyper-IgD and periodic fever syndrome. Blood (2006) 1.02
Carrier frequency of the V377I (1129G>A) MVK mutation, associated with Hyper-IgD and periodic fever syndrome, in the Netherlands. Eur J Hum Genet (2003) 1.01
First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum (2007) 0.99
Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res (1995) 0.95
Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif Tissue Int (1986) 0.92
Mutual augmentation of the induction of the histamine-forming enzyme, histidine decarboxylase, between alendronate and immuno-stimulants (IL-1, TNF, and LPS), and its prevention by clodronate. Toxicol Appl Pharmacol (2005) 0.90
Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci (1998) 0.86
From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. Biomed Res Int (2013) 0.85
Pro-IL-1β accumulation in macrophages by alendronate and its prevention by clodronate. Toxicol Lett (2010) 0.83
Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate. Arch Intern Med (1987) 0.81
The effect of clodronate on a mevalonate kinase deficiency cellular model. Inflamm Res (2012) 0.79
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) (2003) 4.00
Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum (2002) 3.96
EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis (2010) 3.47
Colchicine myopathy and neuromyopathy: two cases with different characteristics. J Clin Rheumatol (2010) 2.17
Rare NLRP12 variants associated with the NLRP12-autoinflammatory disorder phenotype: an Italian case series. Clin Exp Rheumatol (2013) 2.09
Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum (2010) 1.97
Mevalonate kinase genotype in children with recurrent fevers and high serum IgD level. Rheumatol Int (2012) 1.95
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum (2004) 1.89
Intranasal lidocaine and midazolam for procedural sedation in children. Arch Dis Child (2010) 1.61
Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases. Arthritis Rheum (2004) 1.59
Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis (2012) 1.59
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood (2010) 1.43
Guillain-Barré syndrome following adalimumab treatment. Clin Exp Rheumatol (2012) 1.41
The enigma of periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome. Pediatr Infect Dis J (2014) 1.39
Vertebral morphometry by X-ray absorptiometry: which reference data for vertebral heights? Bone (2011) 1.39
Phytothermotherapy in osteoarthritis: a randomized controlled clinical trial. J Altern Complement Med (2011) 1.38
miR-223 is overexpressed in T-lymphocytes of patients affected by rheumatoid arthritis. Hum Immunol (2009) 1.34
Diagnostic utility of ultrasonography versus nerve conduction studies in mild carpal tunnel syndrome. Arthritis Rheum (2008) 1.34
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J Rheumatol (2007) 1.34
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) (2013) 1.29
Autoantibody-mediated cardiac arrhythmias: mechanisms and clinical implications. Basic Res Cardiol (2007) 1.26
Connective tissue diseases and cardiac rhythm disorders: an overview. Autoimmun Rev (2005) 1.25
Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum (2006) 1.21
Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics (2008) 1.20
Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. Ann Rheum Dis (2006) 1.16
Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatol Int (2010) 1.14
Efficacy of anakinra in refractory Behçet's disease sacroiliitis. Clin Exp Rheumatol (2014) 1.12
Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev (2007) 1.11
p52Shc is required for CXCR4-dependent signaling and chemotaxis in T cells. Blood (2007) 1.09
Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim Biophys Acta (2012) 1.09
Biochemical investigation of the effects of human platelet releasates on human articular chondrocytes. J Cell Biochem (2009) 1.09
Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr (2010) 1.07
Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol (2010) 1.06
Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05
Penile involvement in Henoch-Schönlein purpura with good prognosis. Scand J Urol Nephrol (2007) 1.05
Specific recycling receptors are targeted to the immune synapse by the intraflagellar transport system. J Cell Sci (2014) 1.05
Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev (2012) 1.03
The role of infection in Kawasaki syndrome. J Infect (2013) 1.03
Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol Online J (2011) 1.03
Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord (2014) 1.03
A "new" technique for the diagnosis of chondrocalcinosis of the knee: sensitivity and specificity of high-frequency ultrasonography. Ann Rheum Dis (2007) 1.02
Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol (2012) 1.02
Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol (2011) 1.02
Debate around infection-dependent hemophagocytic syndrome in paediatrics. BMC Infect Dis (2013) 1.01
Helicobacter pylori, gastrointestinal symptoms, and metabolic control in young type 1 diabetes mellitus patients. Pediatrics (2003) 1.00
Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol (2008) 1.00
Blau syndrome, clinical and genetic aspects. Autoimmun Rev (2012) 0.99
Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation. J Biol Chem (2006) 0.99
Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int (2008) 0.99
Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford) (2013) 0.98
The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. Int J Rheum Dis (2013) 0.98
A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics (2006) 0.98
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol (2010) 0.98
Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol (2010) 0.97
Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study. Rheumatol Int (2009) 0.95
Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol (2012) 0.95
International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatology (Oxford) (2014) 0.95
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol (2014) 0.94
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol (2013) 0.94
Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet's disease: a case series. Dermatology (2014) 0.94
Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost (2014) 0.93
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm (2013) 0.93
The labyrinth of autoinflammatory disorders: a snapshot on the activity of a third-level center in Italy. Clin Rheumatol (2014) 0.93
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev (2012) 0.92
Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol (2013) 0.92